Catalyst Pharmaceuticals Stock Forecast, Price & News

+0.01 (+0.23 %)
(As of 04/13/2021 11:40 AM ET)
Today's Range
Now: $4.30
50-Day Range
MA: $4.15
52-Week Range
Now: $4.30
Volume16,920 shs
Average Volume1.78 million shs
Market Capitalization$446.45 million
P/E Ratio6.42
Dividend YieldN/A
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Catalyst Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CPRX
Year FoundedN/A



Sales & Book Value

Annual Sales$102.31 million
Cash Flow$0.38 per share
Book Value$0.85 per share


Net Income$31.88 million


Market Cap$446.45 million
Next Earnings Date5/10/2021 (Estimated)


Top Biotech Stocks for Q2 2021
March 18, 2021 |
Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y
March 16, 2021 |
Is CPRX A Good Stock To Buy Now?
December 16, 2020 |
See More Headlines


Overall MarketRank

1.72 out of 5 stars

Medical Sector

228th out of 2,016 stocks

Pharmaceutical Preparations Industry

102nd out of 771 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.3 5 -4 -3 -2 -1 -
+0.01 (+0.23 %)
(As of 04/13/2021 11:40 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions

Is Catalyst Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Catalyst Pharmaceuticals stock.
View analyst ratings for Catalyst Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Catalyst Pharmaceuticals?

Wall Street analysts have given Catalyst Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Catalyst Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 12,370,000 shares, an increase of 29.5% from the March 15th total of 9,550,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the short-interest ratio is presently 7.0 days. Approximately 12.8% of the shares of the company are sold short.
View Catalyst Pharmaceuticals' Short Interest

When is Catalyst Pharmaceuticals' next earnings date?

Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Catalyst Pharmaceuticals

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Tuesday, March, 16th. The biopharmaceutical company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The biopharmaceutical company had revenue of $31.02 million for the quarter, compared to analysts' expectations of $30.06 million. Catalyst Pharmaceuticals had a trailing twelve-month return on equity of 35.04% and a net margin of 60.48%.
View Catalyst Pharmaceuticals' earnings history

How has Catalyst Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CPRX stock has increased by 22.4% and is now trading at $4.31.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CPRX?

4 equities research analysts have issued 12-month target prices for Catalyst Pharmaceuticals' shares. Their forecasts range from $5.50 to $10.00. On average, they expect Catalyst Pharmaceuticals' stock price to reach $7.63 in the next twelve months. This suggests a possible upside of 76.9% from the stock's current price.
View analysts' price targets for Catalyst Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Catalyst Pharmaceuticals' key executives?

Catalyst Pharmaceuticals' management team includes the following people:
  • Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 74, Pay $908.7k)
  • Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 59, Pay $643.31k)
  • Dr. Gary Ingenito, Chief Medical & Regulatory Officer (Age 65, Pay $646.75k)
  • Ms. Alicia Grande, VP, Treasurer & CFO (Age 50)
  • Mr. Brian Elsbernd J.D., Chief Legal & Compliance Officer (Age 57)
  • Mr. Pete Curry Sr., VP of Sales
  • Mr. Jeffrey Del Carmen, Chief Commercial Officer (Age 51)
  • Mr. Philip B. Schwartz, Corp. Sec. (Age 66)
  • Dr. Charles W. Gorodetzky, Consultant (Age 83)

Who are some of Catalyst Pharmaceuticals' key competitors?

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

What is Catalyst Pharmaceuticals' stock symbol?

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.03%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Gary Ingenito and Patrick J Mcenany.
View institutional ownership trends for Catalyst Pharmaceuticals

Which major investors are selling Catalyst Pharmaceuticals stock?

CPRX stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC.
View insider buying and selling activity for Catalyst Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Pharmaceuticals' stock price today?

One share of CPRX stock can currently be purchased for approximately $4.31.

How much money does Catalyst Pharmaceuticals make?

Catalyst Pharmaceuticals has a market capitalization of $447.49 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis.

How many employees does Catalyst Pharmaceuticals have?

Catalyst Pharmaceuticals employs 76 workers across the globe.

What is Catalyst Pharmaceuticals' official website?

The official website for Catalyst Pharmaceuticals is

Where are Catalyst Pharmaceuticals' headquarters?

Catalyst Pharmaceuticals is headquartered at 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134.

How can I contact Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.